Status:
COMPLETED
Simultaneous TransPRK and Corneal Collagen Cross-Linking
Lead Sponsor:
Bruce Allan
Collaborating Sponsors:
Moorfields Eye Hospital NHS Foundation Trust
Conditions:
Keratoconus
Eligibility:
All Genders
18-35 years
Phase:
NA
Brief Summary
Young patients with keratoconus face two problems: disease progression and corneal shape irregularity leading to poor vision even in spectacles. Corneal collagen cross-linking (CXL) is a new treatmen...
Detailed Description
Features which distinguish this trial from previous trials of combined photorefractive keratectomy (PRK) and corneal collagen cross-linking (CXL) are: a rapid, pulsed light, CXL protocol; and a treatm...
Eligibility Criteria
Inclusion
- Patients with progressive stage II or III keratoconus
- CDVA \< 0.00 logMAR or subjective problems with spectacle corrected visual quality (ghost images or light scatter symptoms)
Exclusion
- Active ocular surface disease
- Minimum corneal thickness \<390µm (leaving 325µm residual stromal thickness after transPTK - in line with minimum thickness recommendations for the study CXL protocol)
- Vulnerable groups (patients whose capacity for giving informed consent to participate in the trial may be impaired)
Key Trial Info
Start Date :
August 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2017
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT02208089
Start Date
August 1 2014
End Date
July 1 2017
Last Update
February 8 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Moorfields Eye Hospital NHS Foundation Trust, 162 City Road
London, United Kingdom, EC1V 2PD